ECM
ACAD icon

Endurant Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Endurant Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-32,371
Closed -$672K – 51
2018
Q3 		$672K Buy
+32,371
New +$509K 0.3% 55
2016
Q1 		– Sell
-10,010
Closed -$357K – 87
2015
Q4 		$357K Buy
10,010
+310
+3% +$10.9K 0.12% 75
2015
Q3 		$321K Sell
9,700
-5,300
-35% -$221K 0.11% 73
2015
Q2 		$628K Buy
+15,000
New +$581K 0.19% 80

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Endurant Capital Management's ACAD Position: Q4 2018 in Review

Endurant Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q4 2018, closing a stake of 32,371 shares — an estimated $672K sold.

Endurant Capital Management first reported a position in ACAD in Q2 2015 and held it in 4 quarters. The position peaked at $672K in Q3 2018. 186 funds tracked by Wall St. Rank hold ACAD as of Q4 2018.

  • Endurant Capital Management reported no remaining Acadia Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Endurant Capital Management sold 32,371 Acadia Pharmaceuticals shares in Q4 2018, an estimated $672K.
  • Endurant Capital Management first reported a position in Acadia Pharmaceuticals in Q2 2015 and held it in 4 quarters.
  • Endurant Capital Management's Acadia Pharmaceuticals position peaked at $672K in Q3 2018.
  • 186 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2018.

Based on Endurant Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.